Latest News and Press Releases

TEL AVIV, Israel, March 15, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

TEL AVIV, Israel, March 07, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

TEL AVIV, Israel, March 02, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

TEL AVIV, Israel, Feb. 21, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced today full results from its exploratory Phase 2 study of VB-111 (ofranergene obadenovec) in patients...

TEL AVIV, Israel, Feb. 06, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

TEL AVIV, Israel, Jan. 31, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced today the publication of a paper discussing MOSPD2, a potential novel immuno-oncology target. The paper,...

TEL AVIV, Israel, Jan. 09, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), provides corporate update and reviews anticipated highlights for 2017. Following positive EOP2 meeting on VB-111...

TEL AVIV, Israel, Jan. 06, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced today that it has completed enrollment in the GLOBE Phase 3 study evaluating the efficacy of its lead...

TEL AVIV, Israel, Dec. 05, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), today announced that the independent Data Safety Monitoring Committee (DSMC) met to conduct its first safety...

The study met its primary endpoint, demonstrating disease stabilization and safety, along with a dose-responseNewly released data show evidence of an overall survival benefit for patients treated with...